At a glance

ClinicalIndex Comparison Record

Phase 2Completed· 668 enrolled

Drug / intervention

CVnCoV 6 μg +4 morebiological

Likely dose

CVnCoV 6 μgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04515147

NCT04515147Phase 2Completed

Compare CT.gov

COVID-19: A Phase 2a, Partially Observer-blind, Multicenter, Controlled, Dose-confirmation Clinical Trial to Evaluate the Safety, Reactogenicity and Immunogenicity of the Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adults >60 Years of Age and 18 to 60 Years of Age

CureVac·interventional·Posted Aug 17, 2020·Updated Sep 28, 2023

In Brief

A Phase 2 clinical trial evaluating CVnCoV 6 μg, CVnCoV 12 μg, and 3 other interventions for Coronavirus and 3 related conditions. Completed, enrolled 668 participants across 2 sites in 2 countries.

Detailed Summary

This study aims to evaluate the safety and reactogenicity profile after 1 and 2 dose administrations of investigational SARS-CoV-2 mRNA vaccine (CVnCoV) at different dose levels and to evaluate the humoral immune response after 1 and 2 dose administrations of CVnCoV.

Study Details

Study Typeinterventional

Allocation--

Masking--

Primary Purpose--

ConditionsCoronavirus, Covid19, SARS-CoV-2, Severe Acute Respiratory Syndrome

CountriesPanama, Peru

CollaboratorsGerman Federal Ministry of Education and Research

Timeline

Phase 2CompletedFinished

202120222023202420252026

First PostedAug 2020

Enrollment StartSep 2020

Primary CompletionFeb 2022

TodayJul 2026

First PostedAug 17, 2020

Enrollment StartSep 21, 2020

Primary CompletionFeb 21, 2022

TodayJul 2, 2026

Enrollment to primary: 1.4 yearsPosted 5.9 years ago